1. SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants
- Author
-
John Kubale, Charles Gleason, Juan Manuel Carreño, Komal Srivastava, Gagandeep Singh, Aubree Gordon, Florian Krammer, and Viviana Simon
- Subjects
SARS-CoV-2 ,COVID-19 ,spike-binding antibodies ,protection ,modeling ,antibody durability ,Microbiology ,QR1-502 - Abstract
ABSTRACT The PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) cohort follows health care workers with and without documented coronavirus disease 2019 (COVID-19) since April 2020. We report our findings regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-binding antibody stability and protection from infection in the pre-variant era. We analyzed data from 400 health care workers (150 seropositive and 250 seronegative at enrollment) for a median of 84 days. The SARS-CoV-2 spike-binding antibody titers were highly variable with antibody levels decreasing over the first 3 months, followed by a relative stabilization. We found that both more advanced age (>40 years) and female sex were associated with higher antibody levels (1.6-fold and 1.4-fold increases, respectively). Only six percent of the initially seropositive participants “seroreverted.” We documented a total of 11 new SARS-CoV-2 infections (10 naive participants and 1 previously infected participant without detectable antibodies; P
- Published
- 2022
- Full Text
- View/download PDF